10x Genomics (TXG) said late Monday a US court issued a permanent injunction against the sale of GeoMx products by Bruker (BRKR).
The US District Court for the District of Delaware will enter the injunction in January, which will prohibit Bruker from making, using, selling, or offering to sell the GeoMx Digital Spatial Profiler and associated instruments, reagents, and services for RNA and protein detection in the US.
These products were acquired from NanoString Technologies, according to 10x Genomics.
To ensure the continuity of the ongoing research, 10x said it requested an exemption for GeoMx users who installed an instrument before the trial in November 2023.
Additionally, 10x said that the court upheld the November 2023 jury verdict, which awarded the company $31 million in damages after finding that NanoString's GeoMx Digital Spatial Profiler products infringed patents licensed to 10x.
Neither Bruker nor NanoString immediately responded to MT Newswires' request for comment.
Shares of 10x Genomics were up nearly 2% in after-hours trading. Bruker shares were unchanged.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。